The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

Phase 2

Completed

• Conditions: Parkinson's Disease

• Registration Number: NCT00163085
• Lead Sponsor: Pfizer

Brief Summary

To determine the effects of the NMDA antagonist, CP-101,606, in subjects with Parkinson's Disease

Detailed Description

Not available

Study Timeline

• Study Start: 2005-05
• Study First Submitted: 2005-09-09
• Study First Submitted QC: 2005-09-09
• Study First Posted: 2005-09-13
• Study Completion: 2006-01
• Status Verified: 2006-09
• Last Update Submitted: 2006-09-21
• Last Update Posted: 2006-09-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• 30- 80-year-old PD patients (UK Parkinson's Disease Brain Bank criteria) with a Hoehn & Yahr stage score of 2-5 in the "off" state.

Exclusion Criteria

• Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Dyskinesia Rating Scale

Secondary Outcome Measures

Name	Time	Method
Fingertapping

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇺🇸 Portland, Oregon, United States